UVision360, Inc., an innovative FemTech company, announced expansion of its intellectual property associated with its office-based, compact hysteroscopy and cystoscopy system, LUMINELLE® DTx System in the U.S.
|
RALEIGH, N.C., Sept. 1, 2020 /PRNewswire/ -- UVision360, Inc., an innovative FemTech company, announced expansion of its intellectual property associated with its office-based, compact hysteroscopy and cystoscopy system, LUMINELLE® DTx System in the U.S.
The United States Patent and Trademark Office (USPTO) has issued patent 10,758,214 titled "BIOPSY DEVICE AND METHOD." The allowed claims cover the novel biopsy sleeve, biopsy system which allows for visualization, and a method of collecting a biopsy sample. "With procedures moving out of the hospital and into the gynecologist's office, this patent further protects the uniqueness of the LUMINELLE System," said Allison London Brown, CEO of UVision360. "Over 50% of uterine biopsies are still performed 'blind', meaning a physician is Not employing the use of a hysteroscope during the procedure. This critical patent award and our subsequent product launch will significantly help physicians visualize and sample abnormal tissue without extra instrumentation." More information about the LUMINELLE DTx Hysteroscopy System can be found by contacting info@UVision360.com or visiting www.luminelle360.com About UVision360
SOURCE UVision360, Inc. |
View original content to download multimedia:
